Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors - Concepedia

Concepedia

Publication | Open Access

Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors

DOI Full Paper Access

51

Citations

19

References

2024

Year

Sophia Frentzas, Anna Rachelle Mislang, Charlotte Lemech, Adnan Nagrial, Craig Underhill, W. Wang, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jermaine Coward

Journal for ImmunoTherapy of Cancer

Abstract

NCT04047290.

References

	Year	Citations

Page 1